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1ABSTRACT
Introduction: Despite the introduction of breast conserving surgery, in Sweden mastectomy 
is still annually recommended to 40–50 % (about 3000) of women with breast cancer. 
National guidelines state that, in the absence of contraindications, these women should be 
offered breast reconstruction. Immediate reconstruction has many advantages compared with 
delayed reconstruction but questions have been raised about the method’s oncological safety 
and which method is preferable.  
Aim: The first aim was to clarify whether it is sufficiently safe oncologically to offer breast 
cancer patients primary reconstruction with implants. The next aim was to evaluate different 
techniques for objective evaluation of breast volume and shape. The third and final aim was 
to compare two different expander implants regarding the number of operations needed to 
achieve patient satisfaction, and to measure and compare their cosmetic outcomes objectively 
and subjectively.
Patients and methods: In a long-term follow-up (median 11.5 years) cohort study, 300 
representative invasive breast cancer patients operated with primary reconstruction with 
implants were compared to 300 matched controls operated with mastectomy alone (Paper I). 
In a pilot study, 25 patients were operated with a new crescent-shaped expander implant and 
the result was compared with those seen after surgery with traditional expander implants 
(Paper II). Twelve patients were included, 6 preoperatively and 6 postoperatively, in a 
methodological analysis comparing five different methods for evaluating the volume and 
shape of the breast (Paper III). The final study (Paper IV) was a prospective trial evaluating 
40 patients, randomised  to either a round one-stage permanent expander implant (n=20) or a 
crescent two-stage implant procedure (n=20). The number of operations needed and the 
patients’ satisfaction were evaluated and compared by two panels, one of experts and one of 
lay people. Objective measurement methods for evaluation of volume and contour 
differences between the breasts were tested. Quality of life was evaluated with the SF-36 
health declaration.
Results: There were no significant differences between mastectomy with and without 
primary reconstruction regarding incidence of local and/or regional recurrences, or time to 
start of oncological treatment (Paper I). The outcome with the crescent-shaped expander 
gave an impression of a more naturally shaped breast (Paper II), which was confirmed in the 
randomized study. Of the patients operated with the one-stage procedure, 70 % had revision 
surgery. No major differences were seen between the groups regarding quality of life (Paper
IV). Volume was estimated significantly better with traditional, simpler methods like plastic 
casts compared to modern technology like Magnetic Resonance Imaging and three-
dimensional techniques, which tended to overestimate volume. Shape could be measured 
objectively with a two-dimensional technique based on three-dimensional laser scanning 
(Paper III).
Conclusion: The cohort study with a well-matched control group demonstrates that 
immediate breast reconstruction with implants can be offered and performed on patients with 
invasive breast cancer without any negative effect on oncological safety. The two-stage 
crescent method gave better aesthetic results than the one-stage procedure, which in a 
majority of the patients failed to be a one-stage method. An easy and simple method like 
plastic casts gave more accurate measurements of breast volume than advanced techniques. 
Laser scanning is a new method for objective measurement of shape and symmetry.  
LIST OF ABBREVIATIONS
BCS Breast conserving surgery 
BMI Body mass index 
BP Bodily pain 
BRCA1 Breast cancer susceptibility gene 1  
BRCA2 Breast cancer susceptibility gene 2 
CT  Computer tomography  
DCIS Ductal carcinoma in situ 
CMF Cyclophosphamid, 5-fluorouracil and methotrexate 
DIEP Deep inferior epigastric perforators flap 
DFS Disease free survival 
DM Distant metastasis 
ER Estrogen receptor 
FEC 5-Floururacil, epirubicin and cyclophosphamid 
GH General health  
HRT Hormone replacement therapy 
HRQOL Health related quality of life   
IBR Immediate breast reconstruction 
ICC Intraclass correlation coefficient 
KTH Kungliga tekniska högskolan (Royal institut of technology)
LABC Local advanced breast cancer 
LD Latissimus dorsi  
LR Local recurrence  
MH Mental health  
MRI Magnetic resonance imaging 
NAC Nipple areola complex 
OC Oncological centre 
OS Overall survival 
PF Physical functioning 
RE Emotional role functioning  
RP Physical role functioning 
PR Progesterone receptor 
PRO Patient reported outcome 
RR   Regional recurrence 
SF Social functioning 
SF-36 Medical outcome study 36-item short form 
SIEA Superficial inferior epigastric artery 
SN Sentinel node 
3-D Three-dimensional 
TMG Transverse musculocutaneous gracilis flap 
TNM Tumour node metastasis 
TRAM Transverse rectus abdominis myocutaneous flap 
VT Vitality 
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INTRODUCTION
Survival in breast cancer is high and today there are about 80,000 women living in Sweden 
who have a history of breast cancer [1, 2]. However, despite the availability of breast 
conserving surgery (BCS), removal of the entire breast is still performed in about 40–50% 
of breast cancer patients and many women fear the surgical trauma and feeling of being 
mutilated by a mastectomy [3]. The loss of a breast is a psychological and physical 
traumatic event and influences the quality of life and body image for many women in all 
ages [4-10]. There is a growing demand for breast reconstruction and we now have the 
technique and the possibility to offer breast cancer patients this option in the absence of 
contraindications. The choice between primary and delayed reconstruction has to be made.
Immediate breast reconstruction (IBR) has advantages over delayed reconstruction but 
questions have been raised about oncological safety [11-13].
The main intention in breast reconstruction must be to individualize each reconstructive 
method to meet patients’ expectations and wishes, always taking oncological aspects into 
consideration. Traditionally, women with ductal cancer in situ (DCIS) and T1-2 tumours are 
offered IBR, while those with presumptive radiotherapy or local advanced breast cancer 
(LABC) are recommended delayed procedures [14-16]. The general opinion has been that 
delayed reconstruction should be performed not earlier than two years after adjuvant 
treatment, i.e. after the period with the highest risk of recurrence.
Although several studies indicate that IBR is oncologically safe, many patients and 
physicians are still uncertain about this method [17-32]. There has been a concern that, due 
to more extensive surgery with a higher risk of postoperative complications, IBR may delay 
the oncological treatment. The first aim of this thesis was to evaluate the oncological safety 
of IBR with implants. 
Notwithstanding the development of advanced techniques with microsurgical flap surgery, 
the majority of women offered IBR still undergo reconstruction with implants [33]. 
Traditional breast expander implants, round as well as anatomically shaped, have known 
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drawbacks, such as undesirable fullness of the upper pole and inadequate expansion of the 
lower pole, often leading to poor ptosis of the reconstructed breast [34, 35].
The next aim of the thesis was to evaluate traditional methods with new 2- and 3-D 
techniques for objective measurement and evaluation of breast volume and shape.  
A crescent-shaped expander especially expanding the lower pole of the breast may be 
capable of producing a more natural shape [36]. The final aim of the thesis was to evaluate 
the crescent expander implant and compare its outcome with that of traditional expander 
implants.  
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BACKGROUND
reast cancer 
Epidemiology
 breast cancer varies internationally but in western countries this is the most 
tiology
y of breast cancer is multi-factorial and still not fully known. Hereditary breast 
iagnosis
st cancer diagnosis is based on a triple diagnostic procedure with clinical 
B
The incidence of
common female cancer [37, 38]. In Sweden, more than 7000 women are diagnosed with 
breast cancer annually, which is equivalent to 30% of all female malignancies (Figure 1) [1, 
39]. The mean age at diagnosis is 63 years; 18% are younger than 50 years and 4.5% younger 
than 40 (Figure 2). After rising 1.4% annually in the past few decades, the annual incidence 
of breast cancer in Sweden has stabilized or even decreased in recent years [1, 39]. However, 
in many newly industrialized countries the incidence is increasing rapidly with changing 
lifestyles, indicating environmental changes as important risk factors [1, 40].
E
The etiolog
cancer is considered to be present in less than 10% of the patients, and of those a mutation in 
Breast Cancer susceptibility gene (BRCA) 1 or 2 is the cause in 1/3 of the cases [41, 42]. 
Other risk factors that can influence the development of breast cancer are obesity, alcohol 
habits, smoking, low parity, late and low childbirth, early menarche, late menopause, 
hormone replacement therapy and amount of breast tissue [1]. 
D
Today, brea
examination of the breast, (radiological) mammography/ultrasound and fine-needle 
aspiration/core biopsy. The sensitivity of this triple procedure is very high, with less than 1% 
missed cases [43]. Complimentary methods such as magnetic resonance imaging (MRI) can 
be used.
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Numbers of new invasive breast cancer cases in Sweden by year of 
diagnosis
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Figure 2. 
Source Figure 1-2: www.socialstyrelsen.se/statistik/statistikdatabas
Treatment 
Sweden has national guidelines for the treatment of breast cancer. Today, primary 
treatment in most patients is surgery with additional adjuvant therapy, such as 
chemotherapy, endocrine therapy, radiotherapy and target drugs, administrated as single 
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therapy or in various combinations [1]. About 60% of the patients are operated with BCS 
with removal of only the tumour-bearing part of the breast. After BCS, radiotherapy is 
always recommended in order to reduce the risk of local recurrence and to improve survival 
[44]. In patients with large tumours, multicentric or inflammatory cancer, mastectomy is 
recommended. Patients with advanced tumour stage are offered neoadjuvant therapy before 
surgery [1, 45]. In invasive breast cancer surgery, the operation is always accompanied by a 
staging procedure in the axilla. Axillary clearance with removal of 10–15 lymph nodes has 
been replaced by sentinel node (SN) biopsy in node negative patients. SN is the first node in 
the axilla that drains the breast tumour. Perioperative pathological examination of the SN 
spares 60–70 % of all breast cancer patients from major surgery in the axilla [46-48]. 
Prognosis
Mortality has been relatively stable or slowly decreasing, with approximately 1500 breast 
cancer deaths per year in Sweden (Figure 3) [1, 39]. The improved prognosis may be due to a 
combination of early detection by screening mammography, increased awareness and better 
treatment [1].  
Breast cancer mortality in Sweden by year of diagnosis
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Figure 3.  
Source: www.socialstyrelsen.se/statistik/statistikdatabas
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The main prognostic factors are the patient’s age and the tumour stage according to the 
TNM classification, which is based on the size of the primary tumour (T), and the presence 
of regional lymph node metastases (N) and distant metastases (M) [1, 39, 49]. A 
retrospective American study, published in 1998, gave the following 10-year survival rates: 
Stage 0 patients 95%, Stage 1 patients 88%, Stage 2 patients 66%, Stage 3 patients 36% 
and Stage 4 patients 7% [50]. In Sweden the overall 5-year survival rate in 2007 was  
87.8 % [1, 39]. 
Local recurrence 
Local recurrence (LR) is usually defined as a recurrence of tumour growth in the skin, 
subcutaneous layer or chest wall in the area of the previous mastectomy or in the remaining 
breast after BCS. Quality criteria require that LR after breast conserving surgery for 
invasive cancer should not exceed 15% after 10 years and be less than 10% after 
mastectomy [51, 52]. More skin-sparing mastectomies do not seem to affect the LR rate 
[32, 53, 54].
History of breast cancer surgery 
More than 3500 years ago the ancient Egyptians described breast cancer as an untreatable 
disease, though attempts at treatment are documented in the Edwin Smith Papyrus [55].
Hippocrates (c.460–377 BC) described breast cancer as a humoural disease, in keeping with 
his division of the body fluids. He noted that an untreated tumour was black and hard in 
appearance and eventually penetrated the skin in the form of a black liquid. He also coined 
the word cancer from karkinos, the Greek word for crab. He considered that surgical 
treatment was considered inappropriate since survival was longer for those who did not 
undergo surgery [56]. Galen (129–c. 200 AD) also defined breast cancer as a systemic 
disease; treatment was strictly pharmacological and surgery was considered dangerous 
[57].
Until the 18th century it was widely accepted that Galen had the last word on breast 
cancer’s causes and treatments. During the 18th and 19th centuries, a radical period, the 
humoural theory fell into disrepute and surgery was discussed and reviewed by numerous 
physicians, such as Hunter, Le Cat and others who sometimes used slightly unorthodox 
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methods to convince colleagues [58]. A variety of contemporary theories, some more 
trustworthy than others, linked breast cancer to sexual activity, the harmful effect of 
coagulated milk and mammary veins constricted by depression. However, unlike their 
ancient predecessors, the majority agreed that breast cancer was a local disease curable by 
surgery alone [58]. The advent of anaesthesia, blood transfusion and antimicrobial techniques 
made radical mastectomy possible. The foremost pioneer in this field was the American 
surgeon William Halsted (1852–1922), who developed radical mastectomy [59]. 
In the mid-1900s Bernard Fisher revolutionized cancer treatment with the theory of 
metastasis. As Hippocrates had hypothesised more than 2000 years earlier, he argued that 
breast cancer is a systemic disease in which cancer cells are transported within blood and 
lymphatic fluid, why surgical treatment alone is not sufficient. In 1976, Fisher started a 
randomised study which showed that BCS in conjunction with radiotherapy was as effective 
as radical mastectomy alone [60]. The modern approach to breast cancer surgery was born 
and further developed with the SN biopsy technique [46, 61-64].
Great progress was also being made in oncological treatment such as chemotherapy, 
radiotherapy, and endocrine therapy; together with the surgical developments, this lay the 
foundation for the golden standard for breast cancer treatment in the 1980–90s [1]. 
History of reconstructive breast surgery 
Radical mastectomy extended life but was a mixed blessing. Patients became disfigured and 
often had chronic pain. Dr. Halsted considered these side effects “a necessary evil and since 
the average age was nearly fifty-five years, they were no longer active members of society” 
[59]. Fortunately, this attitude has changed, leading to the development of reconstructive 
breast cancer surgery and a focus on quality of life [65].
Historically, the first reconstruction, when V Czerny transferred a lipoma to the breast, was 
published in 1895 [66]. The first silicone implant was launched by Cronin and Gerow in 
1961 and Arion introduced the first saline expander in 1964 [67, 68]. In 1984, Becker further 
developed the tissue expander, which came into frequent use in the 1990s and served as a 
permanent implant [69]. Since then, five generations of implants have been developed, with 
different covers, contents, sizes and shapes.
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The most common types of implant used for reconstruction today are textured, 
anatomically-shaped silicone shells, filled with silicone, saline or a combination of the two 
(Figure 4) [70].
Figure 4. Different models of breast implants. 
The development of implant-based reconstructions has been accompanied by the 
introduction of several autologous methods. An autologous technique involves transferring 
tissue to the site of the removed breast, either as a pedicled flap or with microsurgical 
technique as a free flap. The most common donor sites are the abdomen, the back or the 
gluteal region. In general, autologous breast reconstruction is more demanding than 
implant-based reconstruction resulting in larger incisions, more scars, longer operating time 
and more complications. On the other hand, in the longer run the aesthetic result may be 
better for some patients [71, 72].  
A commonly used reconstructive technique is the latissimus dorsi (LD) flap, popularized in 
the 1970s [73-75]. The flap is tunnelled under the skin to the mastectomy site as a pedicled 
flap, sometimes combined with an implant to obtain the desired volume. The LD flap can 
also be used alone as an extended flap, with fatty tissue harvested together with the muscle 
[76]. The lateral thoracodorsal flap, also known as the “Göteborg” flap, is a 
fasciocutaneous flap added from the lateral-dorsal thoracic wall to form the lateral part of 
the breast. This technique is also frequently combined with implants [77]. 
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The transverse rectus abdominis myocutaneous flap (TRAM) was introduced for breast 
reconstruction in the 1980s; it can be either pedicled or used as a free flap [78, 79, 80]. 
Today, the free TRAM is often replaced by perforator flaps, such as the deep inferior 
epigastric perforator (DIEP) flap or the superficial inferior epigastric artery (SIEA) flap [81-
84]. With these flaps, the muscle and fascia do not have to be removed from the abdomen. 
Only the skin, the subcutaneous tissue and the vessels are transferred, which has proved to be 
advantageous for the patients in terms of decreased donor-site morbidity and quicker 
recovery [85]. Alternatives are the free gluteal flap [86], the free anterolateral thigh flap [87] 
and the free transverse musculocutaneous gracilis (TMG) flap [88].
Ongoing development of new techniques, such as acellular dermal matrix for use in the lower 
pole of implant reconstructions, and refinement of older methods, such as lipofilling, creates 
new possibilities in the area of reconstructive breast surgery [76, 89, 90].
The choice of a reconstructive method is a multifactorial issue. Primary versus delayed? 
Implants versus autologous tissue, or a combination? Oncological considerations, local 
traditions, the patient’s condition and preferences will influence the decision. Local access to 
professional competence for reconstruction may also affect the choice between IBR and a 
delayed procedure. Breast reconstructions were first performed as a delayed procedure by 
plastic surgeons. The number of IBR has increased in recent years and so has the number of 
breast surgeons performing reconstructive oncoplastic breast surgery. Cooperation between 
breast and plastic surgeons at major breast centres has made IBR more accessible. However, 
the proportion of breast cancer patients who undergo IBR in Sweden is only 6 % [91].
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Quality of life
The concept of health-related quality of life (HRQOL) comprises a wide range of aspects 
with a variety of definitions, mostly focusing on physical functioning, mental health, social, 
emotional and sexual wellbeing in relation to a medical condition and treatment [92, 93].  
Breast cancer survivors is a growing group of women who desire excellent treatment and a 
good quality of life. The breast is involved in many women’s expectations regard to body 
image, breastfeeding and sexual aspects, for instance. The feeling of being mutilated and 
unattractive is still a big issue for many women, especially those facing mastectomy. The 
aim of breast reconstruction is to improve these patients’ HRQOL [94-97].  
Breast cancer surgery does affect women’s body image and many questionnaires have been 
developed for patient-reported outcomes (PRO). Only a few have been validated and 
specifically address breast cancer surgery with the ability to measure the individual 
patient’s outcome. The choice of surgical procedure to recommend with reference to 
HRQOL is a difficult decision [93, 98].
One must not forget that whichever method is chosen for breast reconstruction, the 
procedure inevitably involves more physical trauma than mastectomy alone. A fair number 
of women choose not to have a breast reconstruction which can be an excellent choice for a 
high quality of life, depending on the patient’s preferences [99].  
Aesthetic evaluation 
An objective method for evaluation makes it possible to set standards and thereby compare 
and evaluate the aesthetic results of different surgical techniques. Many attempts have been 
made to objectively evaluate breast shape, volume and contour, both before and after 
surgery. These evaluations involve volume measurement by MRI, computed tomography 
(CT), mammography, water displacement, plastic cups or thermoplastic casts and 
assessment of shape and symmetry by anatomical measurement and three-dimensional (3-
D) techniques (Figure 5) [100-108]. There is now a wide variety of reconstructive methods 
and a constant development, which makes objective evaluation for comparison of results 
even more important. The results of breast reconstruction can be evaluated objectively and 
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subjectively. Subjective evaluation comprises the patient’s satisfaction or a jury’s assessment 
of patient images; this can be a problem since the results are based on people’s opinions in 
accordance with their expectations. A patient may be very unsatisfied with a result that is 
”perfect” from a surgeon’s point of view. On the other hand, a surgeon may find a result poor 
even when the patient is very satisfied (Figure 6, 7 a-c).
Figure 5. Postoperative 3-D laser scan imaging.  
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Figure 6. Result after IBR with an anatomical 
expander on the left side and a mastopexy on 
the right side. This patient was very satisfied 
with the result despite of the upper pole 
fullness seen in figure 6 b. 
Figure 6 (a)
Figure 6 (b) Figure 6 (c)
Figure 7. Postoperative result after a two 
stage reconstruction on the left side and a 
breast reduction on the right side. This 
patient was very dissatisfied while the 
surgeon rated the result as very good. 
Figure 7 (a)
Figure 7 (b) Figure 7 (c)
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SPECIFIC AIMS OF THE THESIS
x To analyse long-term results of IBR with implants with regard to local, regional 
and distant recurrences and survival compared to women operated with 
mastectomy alone. To study whether IBR affects time to postoperative adjuvant 
treatment.   
x To evaluate a consecutive group of patients having immediate or delayed breast 
reconstruction with a new crescent-shaped expander and to compare the results 
with patients operated with round or anatomically-shaped expander implants. 
x To define the most reliable method for objective evaluation of breast volume and 
shape, pre- and postoperatively, in breast cancer patients undergoing primary 
breast reconstruction with implants. 
x To evaluate the crescent-shaped two-stage expander method with a traditional 
permanent round expander implant and to compare this, using objective 
measurements, including 3-D laser scanner, with subjective evaluation of the 
aesthetic outcome. 
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PATIENTS AND METHODS 
Flow chart of patients included in the thesis 
Paper I (1988–2008) 
Retrospective matched cohort 
n=775
Excluded
n=175
Paper III (2004–10) 
Methodological study 
n=12
Paper IV (2004–10) 
Prospective randomised study 
n=70
Preoperative
        n=6 
Postoperative
n=6
IBR Controls
n=300 n=300
Paper II (2002–03) 
Pilot study 
n=95 (98 breasts) 
Two-stage
(Crescent) 
n=20
   Round/anatomical      Crescent expander          expanders IBR             Delayed IBR             Delayed n=14            n=11 (14 breasts) n=33               n=37 
Excluded
(lost to 
follow –up) 
       n=30 
One-stage
(Becker-25)
n=20
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Paper I 
In a retrospective cohort study, 475 consecutive patients with primary breast cancer were 
operated with IBR with implants. The patients had been registered prospectively in a separate 
database and only those with invasive breast cancer with a follow-up of at least 4 years were 
included (n=300). This cohort of patients was matched with women from the Regional Breast 
Cancer Register of Stockholm-Gotland who had been operated with mastectomy without 
IBR. Each case in the IBR group was matched with one control in terms of age, tumour size, 
nodal status and year of operation, with a median follow-up of 11.5 years.  
All patients were discussed pre- and postoperatively at the multidisciplinary team conference. 
Patients with inflammatory breast cancer or tumours adhering to the pectoral muscle or skin 
were not offered IBR, neither were women with high body mass index (BMI) or heavy 
smokers, as they were considered to be unsuitable for implant reconstruction. Patients with 
large tumours, neo-adjuvant chemotherapy and planned for postoperative radiotherapy were 
included, while those reconstructed after earlier ipsilateral breast cancer were classified as 
LR and excluded from the study. 
Mastectomy was performed with earlier scars (if BCS was not radical) and the nipple-areola 
complex (NAC) excised and with the inner blade of the pectoral fascia left intact. The SN 
biopsy technique was introduced in 1998 and gradually replaced axillary clearance in node 
negative patients. All women in the IBR group were operated with permanent or expandable 
implants placed submuscularly to achieve full muscle cover.  
Oncological treatment was based on recommendations and guidelines from the Stockholm 
Cancer Study Group.
The patients were followed for a total of 5 years at the Oncological Department. Patients with 
no sign of recurrences were then referred to the general practitioners for further follow-up. 
The patients in the IBR group were followed separately at the Department of Reconstructive 
Surgery for evaluation and further assessments. 
Variables from clinical records were registered and patients were followed until the end of 
June 2008. Type of breast cancer, Elston grade [109, 110], hormonal status, time to 
oncological treatment, type of chemotherapy, radiotherapy and early complications were 
19
registered, as were incidence of recurrences, time to detection, how the recurrences were 
detected and survival. The results were compared with data from the Oncologic Centre 
(OC) in Stockholm and from the National Cause of Death Register.
Paper II 
In a pilot study, 25 breast cancer patients were operated with a new crescent-shaped 
expander implant; bilateral reconstruction was performed in three of them. Further, medical 
records were reviewed in 70 patients operated with round or anatomically shaped expander 
implants. The crescent expander has a magnetic filling port incorporated in the centre of the 
implant, while the traditional expander has a separate filling port placed subcutaneously. 
Forty-seven patients were operated with IBR and 48 patients had delayed procedures. Nine 
(36 %) of the patients operated with the crescent-shaped expander received radiotherapy 
compared to 12 (17 %) patients in the other group. Data concerning adjuvant treatment, 
complication rate, fullness of the upper pole, the necessity of revision, and the patient’s 
satisfaction were recorded.
Paper III
From the prospective randomised trial (paper IV) evaluating two different implants in IBR,
12 patients were selected for this study and divided into two groups. Breast volume and 
shape were evaluated in six patients preoperatively and in another six postoperatively.
Breast volume was measured in the preoperative group using standardized plastic cups, 
thermoplastic cast material, MRI and 3-D laser scanner. Contour/shape was evaluated with 
a two-dimensional technique based on 3-D laser scan imaging (Figure 8 a, b). The same 
procedures were used for patients in the postoperative group and in addition, volume was 
assessed with another 3-D analysis based on stereophotographic images. The mastectomy 
specimen was measured by fluid displacement in ml (Archimedes’ principle) and by weight 
in grams and served as a control for the volume measurements. For evaluation of shape, the 
opposite healthy breast served as a reference. 
Figure 8. (a) Sagittal sections in 3-D 
laser scan imaging. 
(b) Contour differences between  
the breasts. 
Figure (a) Figure (b)
20
Paper IV 
In order to compare two different expander implants, a prospective randomised study was 
designed. Power estimation was based on experience from paper II and 40 patients were 
needed. Breast cancer patients scheduled for IBR with implants were eligible for 
participation. Seventy patients were included in the study, 40 patients (20 in each group) 
were evaluated, while 30 patients were lost to follow-up. Patients were randomised to 
either a one-stage round permanent expander (Becker 25) featuring a separate filling port, 
or a two-stage crescent-shaped expander (McGhan 133 LV) with an integrated magnetic 
filling port, replaced in a second stage by an anatomical silicon implant.   
Preoperatively, jugulum-nipple distance and ptosis (cm) were recorded. Breast base width 
was measured with a rigid measurement device. Breast volume was measured using 
standardised plastic cups and thermoplastic sheet material (Orfit); photographic images 
were obtained.
All patients were operated by a standard mastectomy. The mastectomy specimen was 
measured by Archimedes’ principle in millilitres and by weight in grams. The number of 
operations, additional revision surgery and complications in the two groups were 
documented. Postoperatively, the patients were measured in the same way as 
preoperatively and additionally by a 3-D laser scanner and two-dimensional evaluation of 
contour differences between the breasts. The patient’s satisfaction regarding shape, volume 
and symmetry was recorded on a scale from 1–6 (1=very bad, 6=very good). Two panels, 
on of experts and one of lay people, evaluated the aesthetic results on the same scale and 
their assessments were compared with the patient’s satisfaction. Postoperatively, the expert 
panel also evaluated indication for further revision surgery in the one-stage group. Quality 
of life was evaluated with SF-36 (Short Form medical outcome) a validated health 
declaration; 36-item, before and after surgery.  
Statistical methods 
Paper I: The McNemar test and the Stuart-Maxwell test were used for pairwise comparison 
of categorical variables. When pairwise comparison was not appropriate, Person’s chi-
square test for categorical variables and the Mann-Whitney-Wilcoxon test for continuous 
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variables were performed. The Kaplan-Meier method was used to calculate disease-free 
survival as well as breast cancer specific survival. Hazard ratios and 95 % confidence 
intervals were estimated with the Cox proportional hazard regression model with 
stratification on the matched pairs. All statistical analyses were performed in STATA/IC 
statistical software, version 10.0.
Paper III: Paired t-test and repeated ANOVA were used to evaluate whether there were 
significant differences between the methods. Pairwise comparisons were made, and the 
Bonferroni connection applied. The validation of the MRI and the three-dimensional 
methods was tested by intraclass correlation coefficient (ICC).
Paper IV: Before the study, a power analysis indicated that a total of 40 patients was 
needed, with 20 in each group, based on a one-sided test alpha=0.05 and a power 1-
beta=0.90, Pi 1=0.25 and Pi 2=0.70. Fisher`s exact test was used for calculation of 
significance, comparing the revision rate in the one-stage and two-stage groups. Tests were 
significant at p < 0.0500. Variables were summarized using standard descriptive statistics 
such as frequencies, means, medians and standard deviations. Sign-tests were applied for 
comparison of patient-based data before and after revision surgery in the one-stage group. 
Mann-Whitney U-tests were applied for evaluation of patients’ final scores between the 
two groups. The kappa-statistic measure of agreement was used to analyse the agreement in 
the indication for revision surgery in the expert group (0.0=poor, 0.81–1.00=almost 
perfect). Paired and unpaired t-tests were used to analyse differences between the groups in 
the SF-36 health declaration. 
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RESULTS
Paper I
The two groups were well matched and comparable, with small differences. The median 
tumour size was 19 and 20 mm; node positive disease was present in 36% and 36.7%; 
further clinical and histopathological characteristics are presented in (Table I).  
Lobular cancers and hormone receptor-positive tumours were more prevalent in the IBR 
group and the patients in this group more often received endocrine treatment. There were no 
significant differences between the two groups in the proportion of patients treated with 
neoadjuvant chemotherapy, in those receiving adjuvant chemotherapy or in those receiving 
postoperative radiotherapy. Furthermore, no differences were seen between the two groups 
in early postoperative complication rates or in time to initiate oncological treatment  
(Table II).
IBR Controls 
n = 300 n = 300 p-value
Age
Median, years 48 48
Range, years 23-70 28-69 
Tumor size (mm) 
Median 19 20
Range 0-100 0-90 
Lymph nodes (%) 
0 64.0 63.3 
1-3 23.0 22.0 
>4 13.0 14.7 
Morphology (%) n = 291 n = 283 
Ductal 66.3 79.9 0.0031
Lobular 27.2 16.2 
Other 6.5 3.9 
Hormone receptor status (%) n = 274 n = 287 
ER + 79.9 68.6 0.0032
n = 251 n = 275 
PR + 71.3 61.1 0.0082
Table I. Patients’ clinical and histopathological characteristics. 
Immediate breast reconstruction (IBR), estrogen receptor (ER), progesterone 
receptor (PR), 
( 1 Stuart-Maxwell test, 2McNemar chi-square test). 
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IBR Controls 
 n = 300  n = 300 p-value1
    0.346Neoadjuvant chemotherapy (%) 13.0  15.7 
Adjuvant chemotherapy (%) n = 292              n = 290 
45.2  47.6     0.431 
Completed chemotherapy (%) n = 122  n = 119 
0.5692 94.3  92.4 
Time to chemotherapy (weeks) n = 112  n = 105 
Median 5.0   5.1       0.3762
Range 2-22   2-33  
Hormonal treatment (%) n = 283  n = 273 
73.8  66.3    0.103 
Radiotherapy (%) n = 289  n = 284 
34.2  32.8    0.825 
Time to radiotherapy (weeks) n = 86  n = 70 
Median  24.1  24.7   0.9022
Range 6-48   5-42  
Complications < 30 days (%) 7.3  6.3    0.622 
Table II. Oncological treatment, time to treatment and complications.  
Immediate breast reconstruction (IBR), (1 McNemar chi-square test unless otherwise 
stated, 2 Person’s chi-square test for categorical variables; Mann-Whitney-Wilcoxon test 
for continuous variables). 
In the analysis of first events, the incidence of all recurrences was 28.4% in the IBR group 
and 32.8 % in the control group. There were no significant differences in either local 
recurrences in the breast (8.2% in the IBR group, 9.0% in the control group) or in the 
regional recurrence rate (8.2% and 9.7%, respectively), while distant metastases were 
significantly more frequent in the control group (20.3% and 27.1%, respectively), p=0.049. 
The mean time to detection of local recurrence was 1.3 years in the IBR group versus 2.2 
years in the control group (Table III). The majority of local recurrences were detected by 
clinical examination (94%); there were no significant differences between the two groups 
in the detection of either regional recurrences or distant metastases. The IBR group had a 
longer survival time; the differences in breast cancer mortality and all-causes mortality 
were statistically significant. 
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Total number of events First event 
IBR Controls p-value1 IBR Controls p-value1
Overall recurrence (%) 28.4 32.8 0.239 
Local recurrence (%) 8.2 9.0 0.879 6.9 6.4 0.590 
Time to detection (years)
Median 1.3 2.2 0.7632 1.3 1.6 0.6732
Range 0.2-11.9 0.5-11.6 0.2-11.9 0.5-11.6 
Regional recurrence 8.2 9.7 0.555 6.5 6.4 1.000 
(%) 
Time to detection (year) 
Median 4.8 1.6 0.0082 2.6 1.5 0.0142
Range 0.1-12.5 0.3-11.0 0.1-11.5 0.3-5.5 
Distant metastases (%) 20.3 27.1 0.049 14.8 20.1 0.081 
Time to detection (year) 
Median 
Range 
2.7 
0.0-12.4 
3.3 
0,0-13.9 
0.3722 2.3 
0.0-12.4 
3.3 0.2882
0.0-13.9 
Table III. Incidence, detection mode and time to detection of recurrence. 
Immediate breast reconstruction (IBR).   1 McNemar chi-square unless otherwise stated, 
(2 Person’s chi-square test for categorical variables; Mann-Whitney-Wilcoxon test for continuous variables). 
Paper II 
Of the 70 patients operated on with round or anatomically shaped expanders, 61 (87%) were 
dissatisfied with the aesthetic result. The main reason for this was asymmetry of form 
caused by fullness of the upper pole of the reconstructed breast. The patient's dissatisfaction 
led to reoperation with an anatomically-shaped permanent implant in 74% (52/70). Patients 
operated with the crescent-shaped expander were followed for a mean of 8 (4–15) months; 
replacement of the crescent expander with a form-stable anatomical implant was performed 
6–8 months after the primary operation. Of the 25 patients operated with the crescent 
procedure, four developed complications. In 23 reconstructions the aesthetic result with the 
crescent-shaped expander was rated as good/very good by the patients.
Paper III
The peroperative volume of the resected breast measured according to the Archimedes 
principal correlated well with its weight (p=0.64) and was defined as the true volume of the 
breast. Statistically significant differences were detected when MRI, 3-D and plastic cups 
were compared with the Archimedes method. In contrast, no significant difference was 
detected between plastic casts (Orfit) (p=0.17) and the Archimedes method.  
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Validations of the volume calculations with the MRI and 3-D methods also showed high 
correlations between the observers in terms of ICC.  
For the postoperative group, the correlations between the results from five different 
measuring methods are shown in Figure 9. As with the preoperative group, the MRI and 3-
D techniques showed statistically significantly larger volumes than the traditional methods. 
Individual differences between the breasts was not detected (p=0.63).
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Figure 9. The correlation between five different methods of volume measurement 
The differences in contour showed larger discrepancies between the breasts in 
postoperative patients than in the unoperated women in the preoperative group (Figure 10). 
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Figure 10. The differences in contour between the breasts expressed in mm, 
A= preoperative and B=postoperative group. 
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Paper IV
Forty women (20 in each group), out of the 70 included, completed the study and were 
followed for a median of 3.5 (range 1.5–5) years after the primary operation. The mean time 
for completing the reconstruction was 18.8 months in the one-stage group and 20.5 months 
in the two-stage group. Age, BMI and volume of the resected breasts were comparable in 
the two groups.
In line with our results in paper III, the best correlation for volume was seen with the plastic 
casts method (Orfit), while the 3-D volume measurements were too high. The final volume 
of the reconstructed breasts and filling frequencies did not differ statistically between the 
groups. A majority of the patients in both groups (17 out of 20) underwent breast 
reduction/mastopexy of the contralateral breast. 
In the one-stage group, 14 out of 20 (70%) women were not satisfied with the aesthetic 
result compared to 2 out of 20 (10%) women in the two-stage group. This difference 
between the groups in terms of corrective surgery was highly significant, p= 0.0002. The 14 
unsatisfied patients in the one-stage group underwent a capsulotomy/ectomy and 
replacement of the permanent expander implant with a form-stable implant. Additional 
abdominal advancement was performed in eight of these patients in order to create a better 
definition of the inframammary fold and ptosis. Three of the patients also had augmentation 
on the contralateral side to achieve symmetry. Moreover, 3 of these 14 patients required a 
third operation because of asymmetries when the final outcome was evaluated at follow-up. 
The two patients in the two-stage group had corrective surgery because of an unduly large 
implant in one case and a too lateral placement of the implant in the other. The two-
dimensional calculations of the upper and lower poles between the breasts demonstrated 
better symmetry in the two-stage group. The expert panel disagreed with the indication for 
revision surgery in 2 of the 14 patients who had revision in the one-stage group. Plastic 
surgeons considered that the main issue for corrective surgery was upper pole fullness and 
poor ptosis, which was in line with our objective two-dimensional analysis.  
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The complication rate was low among the 40 evaluated patients. Two seromas with 
superficial infections occurred in the one-stage group compared to one in the two-stage 
group and could be cured with aspiration and oral antibiotics. 
The patients’, the expert and lay people panels all gave high scores for the final aesthetic 
results. The patients were most satisfied, followed by the experts and then the lay people. 
The lowest scores were seen in the one-stage group before revision. Statistically significant 
differences (p<0.005) in patient satisfaction before and after corrective surgery were found 
in the one-stage group for the parameters shape, size, symmetry and patient’s overall 
aesthetic result (Figure 11). 
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Figure 11. Patient’s opinion regarding aesthetic outcome  
(rated 1-6, 1=very bad, 6=very good).  
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Pre- and postoperative SF-36 scores for both groups and an age-adjusted reference norm 
group are presented in Figure 12. Compared to the norm group, the scores for bodily pain 
were higher in both groups. The scores for the last three domains measuring emotional well-
being were statistically significantly lower preoperatively in both groups compared to the 
norm group. At follow-up, the study groups had statistically significantly improved their 
scores and the score for bodily pain remained higher. Postoperatively, the two-stage group 
showed a higher level for emotional role functioning but the difference was not statistically 
significant.
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Figure 12. SF-36 health profile comparing pre and postoperatively results from both groups compared to 
aged matched norm group.  
Pre.op = preoperatively, post.op = postoperatively. Norm group=Ref.group. PF= physical function,  
RF= physical role functioning, BP= bodily pain, GH=general health,VT= vitality, SF= social functioning
RE= emotional role functioning, MH= mental health. 
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DISCUSSION
Paper I 
To the best of my knowledge, no prospective randomized studies have been published that 
address IBR’s oncological safety. There are several retrospective studies regarding IBR and 
the rate of LR but just a few of them are cohort studies with a controlled design (Table IV) 
[16, 17, 19, 20, 23, 25, 28, 30, 31, 53, 111-114].
In order to evaluate whether a reconstructive procedure could influence the oncological 
outcome, a retrospective cohort study was designed in which patients with invasive breast 
cancer undergoing IBR with implants were compared with a matched group of women 
operated with mastectomy alone. Its strength lay in the well-matched and representative 
patient material and the long follow-up (median 11.5 years). The study provides evidence 
that IBR with implants can be considered a safe procedure oncologically. No significant 
inter-group differences were found in the rates of local recurrence and regional recurrence, 
neither were there any differences in time to initiate adjuvant treatment, number of 
chemotherapy cycles, radiotherapy treatment or in detection mode for recurrences. The rate 
of distant metastases was significantly higher in the control group and the survival figures 
were better for the reconstructed group. These results are in line with other studies, possibly 
as a consequence of confounding factors such as socioeconomic status and selection bias in 
References Tumour 
stage
Study 
period
Number of patients / 
control group 
Follow-up  Local recurrences / 
(month) control group 
Johanson et al, 1989 0-III 1980-86 118 28 6 % 
Noone et al, 1994 0-III 1979-88 306 76 5,2 % 
Slavin et al, 1994 1-IV 1982-90 161 65 11 % 
Newman et al, 1998 I-II 1986-93 372 50 6,2 % 
Ringberg et al, 1999 I-III 1980-94 79 43 5 % 
Kroll et al, 1999 I-II 1986-90 154 72 7 % 
Vanderweyer et al, 2000 0-IV 1990-95 49 / 49 72 4,1 %  / 2,0 % 
Medina-Franco et al, 2002 I-IV 1986-97 173 73 4,5 % 
Langstein et al, 2003 ------ 1988-98 1694 96 2,3 % 
Carlson et al, 2003 0-IV 1989-98 565 65 5,5 % 
Sandelin et al, 2004 I-III 1990-96 203 60 6,5 % 
Greenway et al, 2005 I-II 1984-04 225 49 1,7 % 
McCarthy et al, 2008 I-III 1995-99 309 / 309 68 6,8 %  / 8,1 % 
Petit et al, 2008 I-III 1997-01 518 / 159 70 5,2 %  / 9,4 % 
Eriksen et al, 2011 I-III 1988-06 300 / 300 138 8,2 %  / 9,0 % 
Table IV. Local recurrences after immediate breast reconstruction, previously published studies. 
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inclusion criteria, as IBR was usually not recommended for overweight patients and smokers 
[30, 115]. One limitation was that although the two groups were well-matched, the IBR 
group included more lobular cancers and a higher proportion of hormone receptor-positive 
tumours, which could indicate an overrepresentation of favourable tumours and thereby 
better prognosis in the IBR group. On the other hand, lobular carcinoma does not have a 
better clinical outcome or survival rate compared with ductal carcinoma [116]. A statistical 
correction for hormonal receptor status did not alter the results regarding recurrences, but the 
difference in breast cancer mortality risk was no longer significant.  
There are few prospective studies concerning the aesthetic advantages and disadvantages of 
IBR with and without irradiation and which alternative can be favourable in the long run. In 
our experience, IBR with implants can be combined with irradiation from an oncological 
point of view but the aesthetic results tend to be inferior compared to non-irradiated 
reconstructions [117-123]. Many authors favour autologous tissue reconstructions. However, 
these techniques are less well investigated regarding oncological safety and especially as 
immediate procedures. Moreover, complications are liable to be more frequent and might 
delay adjuvant treatment [12, 13, 124]. As a guide in decision-making, SN biopsy (pre- and 
peroperative) and core biopsy can be used to predict the need for postoperative adjuvant 
therapy [124, 125]. 
A review article on oncological aspects of breast reconstruction in 2005 concluded that there 
was a lack of high-quality evidence on how to advise women considering IBR and IBRs 
possible impact on adjuvant treatment and prognosis [12]. Since then, three long-term 
retrospective follow-up studies with controls, two of them with matched controls (including 
paper I) have been published together with two review articles all pointing in the same 
direction. IBR with implants can safely be offered to breast cancer women in the absence of 
contraindications [29-32]. 
Paper II 
This paper was an early evaluation of the crescent-shaped expander implant that had been 
introduced on the market just before. Patients operated with this new breast expander, in 
immediate as well as in delayed reconstructions, expressed great satisfaction with the 
reconstructed breast after expansion. However, most expander implants designed for a one-
stage procedure failed to meet the patient's expectations since in most cases a satisfactory 
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result required more than one operation. Unfortunately, the crescent-shaped expander 
could not be used as a permanent implant because of the configuration of the central 
magnetic filling port, which is made of metal and could interfere with MRI investigation.
In contrast to traditional filling ports, we did not encounter problems as rotation, pain, or 
difficulties in localising the port. The results suggested that, compared to round and 
anatomically shaped expanders, the crescent-shaped expander gave a more natural shape, 
with less fullness of the upper pole and good ptosis. To find out whether or not these 
results could be verified, a methodological study (paper III) and a prospective 
randomised study (paper IV) were designed.  
Paper III
A methodological study was designed to evaluate new objective 3-D methods for 
measuring breast volume and shape and to compare them with traditional techniques.  
Collaboration was initiated with Professor Stefan Jonson at the Royal Institute of 
Technology (KTH) and photographers at the Department of Medical Imaging, Karolinska 
University Hospital. The idea was to create 3-D images based on stereo photographs and 
to produce a new program for calculating breast volume and shape. This unfortunately 
proved much more difficult than expected and did not come about. Meanwhile a private 
company (Alicona) gave us permission to calculate breast volume from 
stereophotographs of six patients’ images using the 3-D MeX computer program. The 
calculated results from the 3-D MeX program were compared with MRI, plastic casts and 
cups, and a 3-D laser scanner (acquired by Karolinska University Hospital in 2009). 
Compared to 3-D laser scan, the 3-D MeX method gave a slightly better correlation with 
the true values of breast volume, possibly because this method was more sensitive in 
recognising the convexity of the thoracic wall. 
Earlier tests of the accuracy and reproducibility of 3-D evaluation have indicated a good 
potential. Our data suggest, however, that the method’s accuracy as regards aspects of 
volume is questionable [104].  
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The findings confirmed that the method with plastic casts was easy to perform, delivered 
high accuracy and was inexpensive as the same material could be used for several 
evaluations. The plastic cups may be useful for estimating the volume of the female breast 
as data were in fairly good agreement with the true volume.  
Traditional methods gave little or no information about the shape or contour of the breast. 
A two-dimensional sagittal section from 3-D images produced a contour of the breasts, 
permitting a numerical calculation of differences between their upper and lower poles. 
Numerical 3-D differences between the breasts could also be calculated with the Geomagic 
software program but such 3-D calculations could not be obtain that were reproducible. 
This may have been due to the complexity of the program, which had just been introduced 
at the Department of Medical Imaging. This could be a promising method for future 
studies. The introduction of 2- and 3-D scanning techniques added new dimensions to the 
evaluation of shape and volume but the data on volume should be interpreted with caution.  
Paper IV
Various types of breast implants have been developed and evaluated in recent years. The 
overall aim of reconstructive surgery in breast cancer patients has been to improve the 
patient’s quality of life and satisfaction with the outcome, using as few operations as 
possible [3, 7, 8, 92-95]. 
The main problems with traditional implants, both round and anatomically shaped, have 
been the occurrence of upper pole fullness and a lack of ptosis, while the crescent-shaped 
implant seemed to be capable of conferring a more natural shape [36]. A prospective 
randomised study was designed to determine to what extent the round Becker 25 expander 
implant could meet patients’ expectations as a one-stage procedure compared with the two-
stage crescent-shaped expander.  
The strength of this study was its randomised design with two groups that were comparable 
regarding age, BMI and breast volume. Another strength was that the aesthetic outcome 
was evaluated on the basis of both objective and subjective data.  
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The results confirmed that the round permanent expander implant could not meet neither the 
patients’ nor the surgeons’ expectations as a one-stage procedure; the difference between the 
two groups in the number of reoperations was highly statistically significant. These results 
demonstrated the necessity of a two-stage procedure for achieving a good aesthetic outcome. 
The patients in the one-stage group were subjected to more advanced secondary surgery than 
those in the two-stage group, for whom abdominal advancement and augmentation were not 
required to achieve a satisfactory result.
The data further showed that patients in the two groups were equally satisfied with the final 
results after corrective surgery, except that final symmetry was significantly better in the 
two-stage group. The patients expressed the greatest satisfaction, followed by the experts and 
then the lay people.
In this study we also evaluated quality of life pre- and postoperatively in both groups and 
compared the results with an age-related reference group. Both groups scored higher on 
physical functioning and bodily pain than the reference group, which was in line with other 
studies and to be expected [126, 127]. The present data indicated that both groups recovered 
well from the low preoperative scores for emotional well-being and vitality. The two-stage 
group experienced better emotional role functioning than the one-stage group but the number 
of patients was too small to establish statistical significance.  
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CONCLUSIONS
x In the absence of contraindications, immediate breast reconstruction with implants can 
be offered to and performed on patients with invasive breast cancer without any 
negative effect on oncological safety.
x Low-cost plastic cast measurement gave more exact values for breast volume than 
various methods for 3-D measurement. However, more advanced 3-D technology may 
prove to be an important and useful technique for the objective evaluation of 
reconstructive breast surgery. Shape can be measured objectively by two-dimensional 
technique based on 3-D laser scanning.
x The round permanent expander method failed to serve as a one-stage procedure, 
mostly due to upper pole fullness and lack of ptosis. The crescent two-stage expander 
method gave a more natural shape of the breast; both the patients and the panels of 
experts and lay people scored highest for shape and symmetry. Quality of life was 
significantly improved 1.5 years postoperatively in both groups, with no major 
differences between the groups.
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FUTURE PERSPECTIVES
This thesis is based on clinical questions raised in a breast surgeon’s daily work with breast 
cancer women in need of a mastectomy.  
Early studies showed that a mastectomy left 30 % of the women with problems of reduced 
self-esteem, depression, poor sleep and increased anxiety [128]. National guidelines state that 
in the absence of contraindications, these women should be offered breast reconstruction. 
Both IBR and delayed reconstruction are slowly being used more frequently. Despite the 
advantages of IBR, a majority of reconstructions are performed as a delayed procedure. The 
trend is not uniform: IBR is chosen by 20 % of the patients in Stockholm compared to 6 % in 
the rest of Sweden, indicating differences in information and/or demand [91].   
There is an ongoing debate about which reconstructive method is most suitable 
economically, aesthetically and oncologically. One of the factors in this debate is the 
increasing use of post-mastectomy radiotherapy [29, 32, 117-123, 129, 130].  
The tradition at Karolinska University Hospital has been that, in the absence of 
contraindications, women in need of a mastectomy are offered an IBR [28, 131]. Advanced 
surgery with flap technique has not been recommended as a primary procedure for breast 
cancer. One in three IBR reconstructions has been accompanied by radiotherapy even though 
this impairs the reconstruction as a result of more capsular contraction and inferior aesthetic 
results. Compared with mastectomy alone, however, even a poor result with IBR with 
implants can be a better starting-point for a second procedure.
It is not clear that IBR with implant is invariably the best alternative for women seeking 
breast reconstruction. Some studies have shown that in the long run, implant-based 
reconstructions are less aesthetically satisfactory than autologous tissue, but all do not agree 
on this issue [71, 124, 131, 132].
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Still, since implant-based reconstruction probably will be frequently used in the future it is 
important to continue the development of new implants and to evaluate these in all 
important aspects. There is no universal solution; one implant does not suit every patient. 
Moreover, women considering IBR with autologous reconstruction should be included in 
studies until we know more about the oncological safety of these procedures. Preoperative 
mapping can be used to predict the risk of adjuvant treatment [124, 125].  
Today, breast surgery and reconstructive surgery provide a variety of options, which makes 
it more difficult but important to tailor surgery, as well as the oncological treatment, to the 
individual patient (donor site, preferences, expectations, mental health). As each woman is 
unique, we need to be familiar with all the available reconstructive methods and be 
properly informed about our patients’ mental and social situation. When the diagnosis of 
breast cancer is presented to them, patients may be disinclined to accept a reconstructive 
procedure because this aspect may not be their first concern. Patients should have one 
separate consultation for information about the advantages and disadvantages of the various 
forms of reconstruction and have time to consider them before the decision is made at a 
second visit.
For two years now, the four hospitals in Stockholm at which breast and reconstructive 
breast surgery are performed (Södersjukhuset, S:t Göran, Danderyd and Karolinska) have 
regular meetings to discuss issues connected with reconstructive surgery, for example, 
registration of results and complications, possible future studies, education and 
accreditation of reconstructive/oncoplastic breast surgeons.   
Further education in this field is highly important for breast and plastic surgeons to enable 
us to meet patients’ wishes with the best individual recommendations. 
Further studies of reconstructive breast surgery are needed with PRO questionnaires, 
methods for objective measurements and aspects on oncological safety. Prospective 
randomised studies are admittedly difficult but not impossible to perform.  
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SWEDISH SUMMARY 
Titel: Primär rekonstruktion med implantat vid bröstcancer- en studie av onkologisk 
säkerhet och estetiskt resultat. 
Behandlingen av bröstcancer har genomgått stora förändringar de senaste decennierna från 
att initialt avlägsna hela bröstet (mastektomi) till bröstbevarande kirurgi. Förbättrad kunskap 
om bröstcancerns tumörbiologi har bidragit till utveckling av potenta kemo- och 
antihormonella behandlingsstrategier i kombination med strålbehandling.  
Trots införandet av bröstbevarande kirurgi, som utförs i c:a 50-60 %, rekommenderas årligen 
mastektomi hos ca 3000 kvinnor i Sverige. Kvinnor som genomgår mastektomi löper större 
risk att få nedsatt självkänsla, sömnsvårigheter, ökat ångest, depression samt sexuella 
problem. I enlighet med det nationella vårdprogrammet bör alla kvinnor som rekommenderas 
mastektomi erbjudas rekonstruktion av bröstet om inget medicinskt hinder föreligger. De 
psykosociala vinsterna samt de kosmetiska fördelarna med en bröstrekonstruktion är väl 
dokumenterade.  
Den onkologiska säkerheten vid primär rekonstruktion har studerats i retrospektiva studier 
med varierande uppföljning och i de flesta fall utan jämförande kontroller. Resultaten har 
talat för att den lokala återfallsfrekvensen förefaller vara låg och jämförbar med kvinnor som 
genomgått operation utan rekonstruktion. Trots mer än 20 års nationell och internationell 
erfarenhet med primär bröstrekonstruktion med implantat råder fortfarande en viss osäkerhet 
både bland patienter och hos sjukvårdspersonal beträffande den onkologiska säkerheten. Vid 
fall med avancerad bröstcancer och i fall med planerad strålbehandling är indikationen för 
primär rekonstruktion oklar. Detta leder till att patienterna får varierande och otydlig 
information. Primär rekonstruktion med implantat är i Sverige ett förstahandsalternativ. Det 
finns många olika implantat som är kommersiellt tillgängliga. Nackdelen med de flesta 
implantat är att det rekonstruerade bröstet blir för fylligt i den övre delen och saknar det 
naturliga hänget (ptos) jämfört med det friska bröstet.  
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Syftet med studie I var att studera om primär rekonstruktion med implantat kunde påverka 
återfallsfrekvens och överlevnad samt att undersöka om tiden till onkologisk 
tilläggsbehandling fördröjdes. I en retrospektiv långtidsuppföljning (median 11,5 år) 
jämfördes 300 patienter med invasiv bröstcancer opererade med mastektomi och samtidig 
rekonstruktion med implantat med 300 matchade patienter opererade med enbart 
mastektomi. Det förelåg inga signifikanta skillnader mellan grupperna beträffande antalet 
lokala och regionala återfall samt tid till behandling. Färre fjärrmetastaser samt bättre 
överlevnad förelåg i den rekonstruerade gruppen vilket kan bero på en selektion av 
patienter i den rekonstruerade gruppen.
I en pilotstudie (studie II) belystes resultaten av bröstrekonstruktion med ett nytt implantat 
med formen av en halvmåne (crescentformat implantat). Syftet med det nya implantatet var 
att återskapa en mer naturlig form och symmetri då den specifikt expanderar den nedre 
delen av bröstet. Den crescentformade expandern opereras i ett två-stegs förfarande och 
ersätts efter expansion med ett permanent anatomiskt implantat. Studien gav, trots att den 
var liten, ett intryck av att tvåstegsmetoden gav ett bättre estetiskt resultat jämfört med 
traditionella expanderimplantat.  
Studie III var ett metodarbete som validerade olika mätmetoder för bröstvolym och form 
hos sex patienter som skulle genomgå en rekonstruktion samt hos sex patienter som 
genomgått en rekonstruktion. Resultaten visade stor variation mellan de olika 
mätmetoderna, där magnetröntgen och 3-dimensionell teknik visade högre volymer jämfört 
med äldre enklare metoder som vanliga skålar i plast och formbar plast vilken gav den mest 
exakta volymskattningen. Konturskillnader mellan brösten mättes och kvantifierades med 
två-dimensionell teknik baserat från 3-D bilder.
För att konfirmera erfarenheterna från studie II genomfördes en prospektiv randomiserad 
studie (studie IV) där patienter slumpmässigt selekterades till att opereras med den 
crescentformade två-stegsmodellen eller med en rund, permanent, traditionell expander. 
Fyrtio patienter, 20 i varje grupp, evaluerades. Mätmetoder redovisade i studie III användes 
för utvärdering. Dessutom utvärderade patienterna själva samt en panel bestående av 
lekmän och plastikkirurger de kosmetiska resultaten. Det permanenta, runda implantatet 
fallerade som en enstegsmetod och krävde reoperationer i 70% av fallen. Två-stegs 
metoden med det crescentformade implantatet gav bäst form och symmetri.  
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Livskvalitet utvärderades med hjälp av SF-36 som är ett validerat frågeformulär där de 
studerade patienterna jämfördes med en åldersrelaterad normalbefolkning. Resultaten 
visade att de rekonstruerade patienterna återhämtade sig 1,5 år efter operationen och inga 
större skillnader kunde ses mellan de två grupperna. 
Sammanfattning: Primär bröstrekonstruktion med implantat kan erbjudas patienter med 
bröstcancer utan negativ inverkan på den onkologiska säkerheten. Tvåstegsförfarande med 
den crescentformade expandern gav ett bättre resultat jämfört med traditionella 
enstegsimplantat. De äldre enklare teknikerna gav de mest exakta volymsbedömningarna 
jämfört med ny 3-D teknik som dock kunde andvändas som underlag för två-dimensionell 
konturbedömning.
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